Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day: Phase 2 randomized study of modakafusp alfa in patients with relapsed/refractory myeloma finds ORRs were 32% and 41% at 120 and 240 mg arms; median PFS 4.1 and 5.3 months; ORRs higher in patients without prior-BCMA therapy (46% vs. 29%).”
Authors: Sarah Holstein, Shebli Atrash, Hira Mian, Meletios Athanasios Dimopoulos, Fredrik Schjesvold, Shuli Li, Allison Nelson, Dasha Cherepanov, Xavier Parot, Dan Vogl et al.
More posts featuring Robert Orlowski.
